<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="case-report" xml:lang="en" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Open Respir Arch</journal-id><journal-id journal-id-type="iso-abbrev">Open Respir Arch</journal-id><journal-id journal-id-type="pmc-domain-id">4482</journal-id><journal-id journal-id-type="pmc-domain">opresparch</journal-id><journal-title-group><journal-title>Open Respiratory Archives</journal-title></journal-title-group><issn pub-type="epub">2659-6636</issn><publisher><publisher-name>Elsevier</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC12476097</article-id><article-id pub-id-type="pmcid-ver">PMC12476097.1</article-id><article-id pub-id-type="pmcaid">12476097</article-id><article-id pub-id-type="pmcaiid">12476097</article-id><article-id pub-id-type="doi">10.1016/j.opresp.2025.100483</article-id><article-id pub-id-type="pii">S2659-6636(25)00087-6</article-id><article-id pub-id-type="publisher-id">100483</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Clinical Report</subject></subj-group></article-categories><title-group><article-title>Fixed Airflow Limitation in Severe Asthma: Rethinking the Role of Small Airway Disease</article-title><trans-title-group xml:lang="es"><trans-title>Obstrucci&#243;n fija al flujo a&#233;reo en el asma grave: repensando el papel de la enfermedad de la peque&#241;a v&#237;a a&#233;rea</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" id="aut0005"><name name-style="western"><surname>Jim&#233;nez-G&#243;mez</surname><given-names initials="M">Miguel</given-names></name><email>migueljimenezgomez@gmail.com</email><xref rid="aff0005" ref-type="aff">a</xref><xref rid="cor0005" ref-type="corresp">&#8270;</xref></contrib><contrib contrib-type="author" id="aut0010"><name name-style="western"><surname>Garc&#237;a-Moguel</surname><given-names initials="I">Ismael</given-names></name><xref rid="aff0010" ref-type="aff">b</xref></contrib><contrib contrib-type="author" id="aut0015"><name name-style="western"><surname>D&#237;az-Campos</surname><given-names initials="RM">Roc&#237;o Magdalena</given-names></name><xref rid="aff0005" ref-type="aff">a</xref></contrib><aff id="aff0005"><label>a</label>Department of Pulmonology, 12th of October University Hospital, Madrid, Spain</aff><aff id="aff0010"><label>b</label>Department of Allergology, 12th of October University Hospital, Madrid, Spain</aff></contrib-group><author-notes><corresp id="cor0005"><label>&#8270;</label>Corresponding author. <email>migueljimenezgomez@gmail.com</email></corresp></author-notes><pub-date pub-type="collection"><season>Oct-Dec</season><year>2025</year></pub-date><pub-date pub-type="epub"><day>04</day><month>9</month><year>2025</year></pub-date><volume>7</volume><issue>4</issue><issue-id pub-id-type="pmc-issue-id">493901</issue-id><elocation-id>100483</elocation-id><history><date date-type="received"><day>18</day><month>5</month><year>2025</year></date><date date-type="accepted"><day>2</day><month>8</month><year>2025</year></date></history><pub-history><event event-type="pmc-release"><date><day>04</day><month>09</month><year>2025</year></date></event><event event-type="pmc-live"><date><day>28</day><month>09</month><year>2025</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2025-09-28 21:25:17.150"><day>28</day><month>09</month><year>2025</year></date></event></pub-history><permissions><copyright-statement>&#169; 2025 Sociedad Espa&#241;ola de Neumolog&#237;a y Cirug&#237;a Tor&#225;cica (SEPAR). Published by Elsevier Espa&#241;a, S.L.U.</copyright-statement><copyright-year>2025</copyright-year><copyright-holder>Sociedad Espa&#241;ola de Neumolog&#237;a y Cirug&#237;a Tor&#225;cica (SEPAR)</copyright-holder><license><ali:license_ref specific-use="textmining" content-type="ccbyncndlicense">https://creativecommons.org/licenses/by-nc-nd/4.0/</ali:license_ref><license-p>This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="main.pdf"/><abstract id="abs0010"><p>Small airway disease (SAD) remains a challenging and underrecognized driver of fixed airflow obstruction in severe asthma. Impulse oscillometry (IOS) provides valuable insight into peripheral airway dysfunction and allows characterization of different bronchodilator response patterns. We describe two cases of late-onset severe asthma with confirmed SAD by spirometry and IOS, unresponsive to systemic corticosteroids and to biologics, despite optimized high-dose extrafine triple inhaled therapy and adherence. Both patients exhibited persistent airflow obstruction and abnormal IOS parameters, suggesting a resistant SAD phenotype. Importantly, the role of corticosteroid challenge in this subgroup remains unclear, as it failed to predict subsequent biologic response. These observations highlight the clinical utility of IOS in diagnosing and monitoring SAD and reinforce the need for personalized therapeutic approaches to address this treatment-resistant endotype of severe asthma.</p></abstract><trans-abstract xml:lang="es"><p>La enfermedad de la v&#237;a a&#233;rea peque&#241;a constituye un componente dif&#237;cil de diagnosticar en el asma grave con obstrucci&#243;n grave. La oscilometr&#237;a de impulsos (IOS) permite caracterizar la disfunci&#243;n perif&#233;rica y describir distintos patrones de respuesta broncodilatadora, aportando un fenotipado m&#225;s preciso. Presentamos dos casos de asma grave de inicio tard&#237;o con afectaci&#243;n de v&#237;a peque&#241;a confirmada por espirometr&#237;a e IOS, refractarios a corticoides sist&#233;micos y a biol&#243;gicos, a pesar de tratamiento inhalado triple optimizado y buena adherencia. Ambos mostraron obstrucci&#243;n persistente y par&#225;metros oscilom&#233;tricos alterados, sugiriendo un fenotipo resistente. Destacamos que el papel del reto con corticoides en este subgrupo de pacientes sigue siendo incierto, pues no predijo la respuesta posterior a biol&#243;gicos. Estos hallazgos refuerzan el valor de la IOS en el diagn&#243;stico y seguimiento de la afectaci&#243;n de v&#237;a a&#233;rea peque&#241;a, y subrayan la necesidad de estrategias terap&#233;uticas personalizadas.</p></trans-abstract><kwd-group id="kwd0005"><title>Keywords</title><kwd>Small airway dysfunction</kwd><kwd>Impulse oscillometry</kwd><kwd>Severe asthma</kwd></kwd-group><kwd-group xml:lang="es" id="kwd0010"><title>Palabras clave</title><kwd>Enfermedad de peque&#241;a v&#237;a a&#233;rea</kwd><kwd>Oscilometr&#237;a de impulsos</kwd><kwd>Asma grave</kwd></kwd-group><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta></custom-meta-group></article-meta></front><body><p id="par0005">Small airway disease (SAD) remains a silent driver of fixed airflow obstruction in severe asthma&#8212;underdiagnosed,<xref rid="bib0055" ref-type="bibr"><sup>1</sup></xref> undertreated, and often unresponsive to biologics. In patients with persistent obstruction despite treatment, a systemic corticosteroid trial may help identify the diagnosis and assess reversibility.<xref rid="bib0060" ref-type="bibr"><sup>2</sup></xref> The ATLANTIS study<xref rid="bib0065" ref-type="bibr"><sup>3</sup></xref> highlighted a strong association between spirometry-defined airflow limitation, SAD, and type 2 inflammation biomarkers. Notably, SAD has been independently associated with increased mortality, particularly from respiratory causes.<xref rid="bib0070" ref-type="bibr"><sup>4</sup></xref></p><p id="par0010">Impulse oscillometry (IOS) has emerged as a valuable method for detecting SAD,<xref rid="bib0055" ref-type="bibr"><sup>1</sup></xref> especially spirometry fails to capture peripheral airway dysfunction. IOS is particularly suited for functional phenotyping in asthma, though its routine clinical application remains limited. SAD can be identified by IOS parameters such as elevated resistance (R) difference between 5 and 20&#160;Hz (R5-20), reduced reactance at 5&#160;Hz (X5), or an increased area under the reactance curve (AX).<xref rid="bib0075" ref-type="bibr"><sup>5</sup></xref> Although standardized thresholds for bronchodilator response in IOS are not yet universally established, commonly used criteria include a &#8805;40% decrease in R 5&#160;Hz, &#8805;50% increase in X 5&#160;Hz and &#8805;80% decrease in AX relative to baseline.<xref rid="bib0080" ref-type="bibr"><sup>6</sup></xref> Current therapeutic strategies for SAD include triple inhaled therapy.<xref rid="bib0085" ref-type="bibr"><sup>7</sup></xref> Biologics have shown encouraging results,<xref rid="bib0055" ref-type="bibr"><sup>1</sup></xref> particularly when initiated early.<xref rid="bib0085" ref-type="bibr"><sup>7</sup></xref> However, the value of corticosteroid challenge in predicting response remains unclear.</p><p id="par0015">We present two cases of late-onset severe asthma with confirmed SAD and persistent functional impairment, despite confirmed adherence to optimized triple inhaled therapy with extrafine high-dose beclometasone/formoterol/glycopyrronium. Asthma-related comorbidities &#8211; including chronic rhinosinusitis, gastroesophageal reflux disease, obstructive sleep apnea, vocal cord dysfunction, obesity, and anxiety &#8211; were systematically assessed and appropriately managed. Microbiological and autoimmune tests were negative. Neither patient showed evidence of allergic sensitization or allergic bronchopulmonary aspergillosis.</p><p id="par0020">Case one, was a 58-year-old man, former smoker (10 pack-years in early adulthood), with asthma control test (ACT) score of 10. Case two was a 57-year-old woman, never smoker, with ACT of 22. Asthma diagnosis was supported in both cases by prior bronchodilator positive test, and clinical response to appropriate therapy.</p><p id="par0025">Case 1 had peripheral eosinophila (700/&#956;L), FeNO of 16&#160;ppb. Case 2 showed undetectable eosinophils and FeNO 25&#160;ppb.</p><p id="par0030">High-resolution CT scan excluded mucus plugging, mosaic attenuation or other parenchymal abnormalities in both cases.</p><p id="par0035">Functional evaluation, including both spirometry and IOS, confirmed baseline SAD in both cases. Case 1 (post-bronchodilator) had a forced vital capacity (FVC) of 3480&#160;mL (90% predicted), forced expiratory volume in one second (FEV<sub>1</sub>) of 1350&#160;mL (44%) and FEV<sub>1</sub>/FVC ratio of 39%, indicating severe airway obstruction. Mid-expiratory flow (MEF<sub>25&#8211;75%</sub>) was markedly reduced at 370&#160;mL/s (14%) and FEV<sub>3</sub>/FVC 59%. IOS revealed increased R5-20 (0.23&#160;kPa/L/s), increased R5 (0.57&#160;kPa/L/s; 190% of predicted) with preserved R20 (0.34&#160;kPa/L/s; 131%), markedly reduced X5 (&#8722;0.29&#160;kPa/L/s) and elevated AX (3.50&#160;kPa/L), supporting the presence of SAD. Despite a significant bronchodilator response in FEV<sub>1</sub> (+22%, +240&#160;mL), IOS abnormalities persisted. Case 2 had an FVC of 1720&#160;mL (64%), FEV<sub>1</sub> 920&#160;mL (43%), FEV<sub>1</sub>/FVC 53%, MEF<sub>25&#8211;75%</sub> 250&#160;mL/s (12%) and FEV<sub>3</sub>/FVC 74%. IOS revealed abnormal peripheral airway metrics: R5-20 0.24&#160;kPa/L/s, R5 0.47&#160;kPa/L/s (120%), R20 0.23&#160;kPa/L/s (69%), X5 &#8722;0.28&#160;kPa/L/s and AX 2.29&#160;kPa/L. No bronchodilator response was observed, and IOS values remained essentially unchanged, further confirming lack of reversibility.<xref rid="bib0055" ref-type="bibr"><sup>1</sup></xref></p><p id="par0040">A two-week course of oral prednisone (40&#160;mg daily) was administered to both patients. However, neither showed significant clinical (ACT score), spirometry, or IOS improvement. In case 1, lung function even deteriorated slightly: FVC increased to 3650&#160;mL (95%) but FEV<sub>1</sub> remained low at 1370&#160;mL (45%), FEV<sub>1</sub>/FVC at 38%, and R5Hz increased to 0.63&#160;kPa/L/s. In case 2, lung function remained essentially unchanged, indicating no significant response to a corticosteroid trial.</p><p id="par0045">Both patients were initiated on biologic therapy according to their phenotypes, case one with mepolizumab and case two with Tezepelumab.<xref rid="bib0085" ref-type="bibr"><sup>7</sup></xref> After three months, a comprehensive re-evaluation showed no meaningful improvement in clinical, spirometric, or IOS parameters (<xref rid="fig0005" ref-type="fig">Fig. 1</xref>). In case 1, FEV<sub>1</sub> remained at 1370&#160;mL (45%) and MEF<sub>25&#8211;75%</sub> at 370&#160;mL/s (14%), while R5&#160;Hz and R20&#160;Hz slightly worsened. Due to lack of clinical and functional improvement after six months of treatment with Mepolizumab, biologic therapy was switched to Benralizumab. However, no significant improvement was observed after three additional months. In case 2, FEV<sub>1</sub> was stable at 910&#160;mL (41%), FVC at 1740&#160;mL (65%), and FEV<sub>1</sub>/FVC at 52%, with persistent negative bronchodilator response. Tezepelumab was maintained as it improved asthma control. Our observations are consistent with Carpagnano et al., <xref rid="bib0090" ref-type="bibr"><sup>8</sup></xref> who found limited IOS and spirometric improvement after Tezepelumab in a subgroup of patients with established SAD, despite improvements in symptom control and exacerbations.<fig id="fig0005" position="float" orientation="portrait"><label>Fig. 1</label><caption><p>Spirometric and oscillometric evolution in two patients with severe asthma and confirmed small airway disease. Despite optimized therapy, both cases (case 1: blue, case 2: yellow) showed persistent airflow obstruction and abnormal IOS parameters. No meaningful functional response was observed following systemic corticosteroids or biologic treatment.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="lk005" position="float" orientation="portrait" xlink:href="gr1.jpg"/></fig></p><p id="par0050">These cases underscore a clinically significant subgroup of severe asthma with persistent SAD that appears refractory to corticosteroids and biologics. Lung function remains a crucial parameter for assessing clinical remission, alongside symptom and exacerbation control.<xref rid="bib0095" ref-type="bibr"><sup>9</sup></xref> These observations suggest a potential SAD phenotype defined by fixed airflow obstruction and limited reversibility. Even with optimized inhaled and biologic therapy, some patients demonstrate minimal functional response, highlighting a treatment-resistant endotype. A potential strategy in these patients could be switching to a biologic with a different mechanism of action. In a recent study, switching biologic therapy led to improved lung function and asthma control in patients not responding to initial treatment.<xref rid="bib0100" ref-type="bibr"><sup>10</sup></xref> While IOS provides a sensitive tool for diagnosis and monitoring SAD, its findings in these cases indicate structural or non-type 2 inflammatory changes may underlie resistance. Further studies are urgently needed to elucidate the mechanisms underlying corticosteroid and biologic resistance in SAD, and to inform the development of more effective, personalized therapies for this potentially distinct SAD endotype.</p><p id="par0055">These cases call for a paradigm shift: lung function&#8212;and especially small airway evaluation through IOS&#8212;must regain prominence in defining asthma control and in guiding therapeutic and prognostic decisions.</p><sec id="sec0005"><title>Artificial intelligence</title><p id="par0060">During the preparation of this worth the authors used CHAT GPT 4 solely to assist with language editing under the authors&#8217; supervision. After using this tool/authors reviewed and edited the content as needed and take full responsibility for the content of the publication.</p></sec><sec id="sec0010"><title>Informed consent</title><p id="par0065">Each patient provided written informed consent for the publication.</p></sec><sec id="sec0015"><title>Funding</title><p id="par0070">We declare that this research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.</p></sec><sec id="sec0020"><title>Authors&#8217; contributions</title><p id="par0075">MJG and RMDC contributed to data acquisition, writing and manuscript review. IGM contributed to clinical management, data interpretation and manuscript review. All authors approved the final version of the article.</p></sec><sec id="sec0025"><title>Conflicts of interest</title><p id="par0080">The following authors declare having received fees for lectures and congress participation from the listed companies (alphabetic order): MJG (Chiesi, FAES, GSK, Sanofi), RMDC (AstraZeneca, GEBRO, GSK, Sanofi), IGM has been on Advisory boards of: AstraZeneca, GSK, Novartis, Sanofi Genzyme, Stallergenes, and received speaker's honoraria from: Allergy therapeutics, ALK-Abell&#243;, AstraZeneca, Chiesi, GSK, Leti, Mundipharma, Novartis, Orion Pharma, Pfizer, Sanofi Genzyme, Stallergenes, and Teva.</p></sec></body><back><ref-list id="bibl0005"><title>References</title><ref id="bib0055"><label>1</label><element-citation publication-type="journal" id="sbref0055"><person-group person-group-type="author"><name name-style="western"><surname>Menzella</surname><given-names>F.</given-names></name><name name-style="western"><surname>Antonicelli</surname><given-names>L.</given-names></name><name name-style="western"><surname>Cottini</surname><given-names>M.</given-names></name><name name-style="western"><surname>Imeri</surname><given-names>G.</given-names></name><name name-style="western"><surname>Corsi</surname><given-names>L.</given-names></name><name name-style="western"><surname>Di Marco</surname><given-names>F.</given-names></name></person-group><article-title>Oscillometry in severe asthma: the state of the art and future perspectives</article-title><source>Expert Rev Respir Med</source><volume>17</volume><year>2023</year><fpage>563</fpage><lpage>575</lpage><pub-id pub-id-type="doi">10.1080/17476348.2023.2237872</pub-id><pub-id pub-id-type="pmid">37452692</pub-id></element-citation></ref><ref id="bib0060"><label>2</label><mixed-citation publication-type="other" id="oref0010">Global Strategy for Asthma Management and Prevention 2024. Global Initative for Asthma (GINA). Available from: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://ginasthma.org/2024-report/" id="intr0005">https://ginasthma.org/2024-report/</ext-link> [accessed March 2025].</mixed-citation></ref><ref id="bib0065"><label>3</label><element-citation publication-type="journal" id="sbref0065"><person-group person-group-type="author"><name name-style="western"><surname>Kole</surname><given-names>T.M.</given-names></name><name name-style="western"><surname>Vanden Berghe</surname><given-names>E.</given-names></name><name name-style="western"><surname>Kraft</surname><given-names>M.</given-names></name><name name-style="western"><surname>Vonk</surname><given-names>J.M.</given-names></name><name name-style="western"><surname>Nawjin</surname><given-names>M.C.</given-names></name><name name-style="western"><surname>Siddiqui</surname><given-names>S.</given-names></name><etal/></person-group><article-title>Predictors and associations of the persistent airflow limitation phenotype in asthma: a post-hoc analysis of the ATLANTIS study</article-title><source>Lancet Respir Med</source><volume>11</volume><year>2023</year><fpage>55</fpage><lpage>64</lpage><pub-id pub-id-type="doi">10.1016/S2213-2600(22)00185-0</pub-id><pub-id pub-id-type="pmid">35907424</pub-id></element-citation></ref><ref id="bib0070"><label>4</label><element-citation publication-type="journal" id="sbref0070"><person-group person-group-type="author"><name name-style="western"><surname>Quintero Santofimio</surname><given-names>V.</given-names></name><name name-style="western"><surname>Knox-Brown</surname><given-names>B.</given-names></name><name name-style="western"><surname>Potts</surname><given-names>J.</given-names></name><name name-style="western"><surname>Bartlett-Pestell</surname><given-names>S.</given-names></name><name name-style="western"><surname>Feary</surname><given-names>J.</given-names></name><name name-style="western"><surname>Amaral</surname><given-names>A.F.S.</given-names></name></person-group><article-title>Small airways obstruction and mortality: findings from the UK Biobank</article-title><source>Chest</source><volume>166</volume><year>2024</year><fpage>712</fpage><lpage>720</lpage><pub-id pub-id-type="doi">10.1016/j.chest.2024.04.016</pub-id><pub-id pub-id-type="pmid">38797279</pub-id><pub-id pub-id-type="pmcid">PMC11492227</pub-id></element-citation></ref><ref id="bib0075"><label>5</label><element-citation publication-type="journal" id="sbref0075"><person-group person-group-type="author"><name name-style="western"><surname>Chan</surname><given-names>R.</given-names></name><name name-style="western"><surname>Gochicoa-Rangel</surname><given-names>L.</given-names></name><name name-style="western"><surname>Cottini</surname><given-names>M.</given-names></name><name name-style="western"><surname>Gaillard</surname><given-names>E.A.</given-names></name><name name-style="western"><surname>Ducharme</surname><given-names>F.M.</given-names></name><name name-style="western"><surname>Galatn</surname><given-names>S.P.</given-names></name><etal/></person-group><article-title>Ascertainment of small airways dysfunction using oscillometry to better define asthma control and future Risk</article-title><source>Chest</source><year>2025</year><pub-id pub-id-type="doi">10.1016/j.chest.2024.12.020</pub-id><pub-id pub-id-type="pmcid">PMC12106962</pub-id><pub-id pub-id-type="pmid">39734054</pub-id></element-citation></ref><ref id="bib0080"><label>6</label><element-citation publication-type="journal" id="sbref0080"><person-group person-group-type="author"><name name-style="western"><surname>Carpagnano</surname><given-names>G.E.</given-names></name><name name-style="western"><surname>Portacci</surname><given-names>A.</given-names></name><name name-style="western"><surname>Dragonieri</surname><given-names>S.</given-names></name><name name-style="western"><surname>Montagnolo</surname><given-names>F.</given-names></name><name name-style="western"><surname>Iorillo</surname><given-names>I.</given-names></name><name name-style="western"><surname>Lulaj</surname><given-names>E.</given-names></name><etal/></person-group><article-title>Managing small airway disease in patients with severe asthma: transitioning from the &#8220;silent zone&#8221; to achieving &#8220;quiet asthma&#8221;</article-title><source>J Clin Med</source><volume>13</volume><year>2024</year><fpage>2320</fpage><pub-id pub-id-type="doi">10.3390/jcm13082320</pub-id><pub-id pub-id-type="pmid">38673593</pub-id><pub-id pub-id-type="pmcid">PMC11051485</pub-id></element-citation></ref><ref id="bib0085"><label>7</label><element-citation publication-type="journal" id="sbref0085"><person-group person-group-type="author"><name name-style="western"><surname>Greig</surname><given-names>R.</given-names></name><name name-style="western"><surname>Chan</surname><given-names>R.</given-names></name><name name-style="western"><surname>Fardon</surname><given-names>T.C.</given-names></name><name name-style="western"><surname>Lipworth</surname><given-names>B.J.</given-names></name></person-group><article-title>Real world effects of tezepelumab on small airways dysfunction in severe refectory asthma</article-title><source>Ann Allergy Asthma Immunol</source><year>2025</year><pub-id pub-id-type="doi">10.1016/j.anai.2025.01.024</pub-id><pub-id pub-id-type="pmid">39870209</pub-id></element-citation></ref><ref id="bib0090"><label>8</label><element-citation publication-type="journal" id="sbref0090"><person-group person-group-type="author"><name name-style="western"><surname>Carpagnano</surname><given-names>G.E.</given-names></name><name name-style="western"><surname>Dragonieri</surname><given-names>S.</given-names></name><name name-style="western"><surname>Resta</surname><given-names>E.</given-names></name><name name-style="western"><surname>Lulaj</surname><given-names>E.</given-names></name><name name-style="western"><surname>Montagnolo</surname><given-names>F.</given-names></name><name name-style="western"><surname>Portacci</surname><given-names>A.</given-names></name><etal/></person-group><article-title>Short-term tezepelumab effectiveness in patients with severe asthma: a multicenter study</article-title><source>J Asthma Off J Assoc Care Asthma</source><volume>62</volume><year>2025</year><fpage>456</fpage><lpage>464</lpage><pub-id pub-id-type="doi">10.1080/02770903.2024.2409987</pub-id><pub-id pub-id-type="pmid">39325583</pub-id></element-citation></ref><ref id="bib0095"><label>9</label><element-citation publication-type="journal" id="sbref0095"><person-group person-group-type="author"><name name-style="western"><surname>Busse</surname><given-names>W.W.</given-names></name><name name-style="western"><surname>Chupp</surname><given-names>G.</given-names></name><name name-style="western"><surname>Corbridge</surname><given-names>T.</given-names></name><name name-style="western"><surname>Stach-Klysh</surname><given-names>A.</given-names></name><name name-style="western"><surname>Oppenheimer</surname><given-names>J.</given-names></name></person-group><article-title>Targeting asthma remission as the next therapeutic step toward improving disease control</article-title><source>J Allergy Clin Immunol Pract</source><volume>12</volume><year>2024</year><fpage>894</fpage><lpage>903</lpage><pub-id pub-id-type="doi">10.1016/j.jaip.2024.01.044</pub-id><pub-id pub-id-type="pmid">38320720</pub-id></element-citation></ref><ref id="bib0100"><label>10</label><element-citation publication-type="journal" id="sbref0100"><person-group person-group-type="author"><name name-style="western"><surname>Scioscia</surname><given-names>G.</given-names></name><name name-style="western"><surname>Nolasco</surname><given-names>S.</given-names></name><name name-style="western"><surname>Campisi</surname><given-names>R.</given-names></name><name name-style="western"><surname>Quarato</surname><given-names>C.M.I.</given-names></name><name name-style="western"><surname>Caruso</surname><given-names>C.</given-names></name><name name-style="western"><surname>Pelaia</surname><given-names>C.</given-names></name><etal/></person-group><article-title>Switching biological therapies in severe asthma</article-title><source>Int J Mol Sci</source><volume>24</volume><year>2023</year><fpage>9563</fpage><pub-id pub-id-type="doi">10.3390/ijms24119563</pub-id><pub-id pub-id-type="pmid">37298514</pub-id><pub-id pub-id-type="pmcid">PMC10253346</pub-id></element-citation></ref></ref-list></back></article></pmc-articleset>